SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended | |
|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
|
| Significant Accounting Policies Textual Abstract | |||
| Increase in revenue due to change in estimate due to consideration ultimately received | $ 100 | ||
| Deferred revenue recognized | $ 443 | ||
| Revenue Recognition Recognized | the estimated revenue expected to be recognized in the future amounts to $2.4 million, | ||
| Allowance for credit losses | $ 234 | $ 192 | |
| Outstanding warrants and share option plans | 6,973,007 | 357,779 | |
| Goodwill impairment charges | $ 2,800 | ||
| Acquired in-process research and development expense related to the Oratech asset acquisition | $ 4,900 | ||
| SCI Products [Member] | Minimum [Member] | |||
| Significant Accounting Policies Textual Abstract | |||
| Service policy | 1 year | ||
| SCI Products [Member] | Maximum [Member] | |||
| Significant Accounting Policies Textual Abstract | |||
| Service policy | 10 years | ||
| X | ||||||||||
- Definition Represent the change in estimate of variable consideration increase decrease No definition available.
|
| X | ||||||||||
- Definition Revenue Recognition Recognized No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of allowance for credit loss on accounts receivable, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of asset recognized from cost for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|